GlaxoSmithKline Pharmaceuticals Limited Crosses INR 1,000 Crores In Topline (+8.1%) As Key Portfolios Deliver
Mumbai, India - GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced today its financial results for the third quarter ended December 31, 2025. During the quarter, the Company witnessed growth across its key portfolios, driving overall topline expansion, while profitability was well-managed through cost discipline.
During the quarter, Revenue from Operations was INR 1,023 Crores and Profit After Tax (PAT) was INR 277 Crores. EBIDTA margins grew by 520 basis points (bps) to 35.9%, driven by improved gross margins and operating leverage.
The General Medicines portfolio delivered competitive performance, with top five promoted brands growing ahead of market [EI>100*, Source: IQVIA]. These include flagship brands, Augmentin, Ceftum and T-Bact, which continue to sustain leadership in their respective segments. The Vaccines business saw market share expansion, driven by strong demand and continued leadership in the self-pay private market for paediatric vaccines. Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted) continues to build awareness and adoption as conversations on preventive healthcare and adult immunisation gain foothold within a growing community of Healthcare Practitioners (HCPs).
Launched in August 2025, the Oncology business is gaining traction, led by specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib). During the quarter, the Company expanded engagement with the Oncology fraternity and made steady progress in reaching patients with endometrial and recurrent ovarian cancer.
Results of the landmark Phase III trial (RUBY-1) are set to benefit a broader set of patients with endometrial cancer. The trial evaluated dostarlimab plus standard chemotherapy as first-line treatment in primary advanced or recurrent endometrial cancer. The results demonstrated meaningful improvement in progression-free survival and overall survival across the population under trial, reinforcing the benefit of the treatment to patients of primary advanced and recurrent endometrial cancer.1 2
Bhushan Akshikar, Managing Director, GSK India, said: "By moving immunotherapy from later lines to initial standard of care, the RUBY-1 trial has established a new paradigm in first-line treatment of endometrial cancer, and is now approved for this indication in India. The positive results on progression-free survival and overall survival in the population under trial will simplify decision-making for HCPs on treatment lines and benefit a wide range of endometrial cancer patients. Supported by comprehensive patient support and financing initiatives, the Company is leaving no stone unturned to ensure patients with cancer receive the highest standard of care."
The Company’s competitive performance comes against the backdrop of the broader macro environment and efforts to mitigate internal supply challenges. The implementation of the New Labour Codes 2025 did not have a material impact on the Company.
About GSK India: GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit GSK-India.com.
Media Contact: Communications and Government Affairs
Carson Dalton – carson.a.dalton@gsk.com
Farah Bookwala - farah.a.bookwala@gsk.com
1 Mirza MR, and RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2145-2158.
2 Powell MA, et al.. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Aug;35(8):728-738.
*The Evolution Index (EI) is a metric used to evaluate the performance of a product relative to the overall market growth.
